> top > docs > PMC:7253482 > spans > 15015-15383 > annotations

PMC:7253482 / 15015-15383 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T91 23-33 Body_part denotes amino-acid http://purl.org/sig/ont/fma/fma82739
T92 284-289 Body_part denotes helix http://purl.org/sig/ont/fma/fma60992

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T4 284-289 Body_part denotes helix http://purl.obolibrary.org/obo/UBERON_0002488

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T90 210-212 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T91 210-212 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2
T92 240-247 http://purl.obolibrary.org/obo/PR_000018263 denotes peptide

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T172 23-28 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T173 29-33 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T174 210-212 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387
T175 240-247 Chemical denotes peptide http://purl.obolibrary.org/obo/CHEBI_16670

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T5 87-110 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes neutralizing antibodies http://purl.bioontology.org/ontology/MEDDRA/10058063

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T41 335-345 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T18701 0-7 RB denotes Firstly
T74266 7-8 -COMMA- denotes ,
T36827 9-11 PRP denotes we
T39186 12-17 VBD denotes found
T6773 18-22 IN denotes that
T13224 23-33 JJ denotes amino-acid
T54008 34-43 NN denotes diversity
T35302 44-47 VBD denotes was
T93591 48-56 VBN denotes elevated
T90961 57-59 IN denotes at
T69090 60-65 VBN denotes known
T86793 66-74 NNS denotes epitopes
T61088 75-83 VBN denotes targeted
T53019 84-86 IN denotes by
T30461 87-99 VBG denotes neutralizing
T32200 100-110 NNS denotes antibodies
T83554 110-111 -COMMA- denotes ,
T32640 112-116 JJ denotes such
T51281 117-119 IN denotes as
T69890 120-123 DT denotes the
T83248 124-134 JJ denotes N-terminal
T49099 135-141 NN denotes domain
T58919 142-145 CC denotes and
T18721 146-149 DT denotes the
T18570 150-166 JJ denotes receptor-binding
T60790 167-174 NNS denotes domains
T18812 174-175 -COMMA- denotes ,
T96660 176-179 CC denotes and
T11216 180-187 VBN denotes reduced
T27277 188-190 IN denotes in
T89562 191-194 DT denotes the
T7777 195-202 NNS denotes regions
T23472 203-205 IN denotes in
T66095 206-209 DT denotes the
T52990 210-212 NN denotes S2
T69246 213-219 NN denotes domain
T76095 219-220 -COMMA- denotes ,
T33023 221-225 JJ denotes such
T94778 226-228 IN denotes as
T12698 229-232 DT denotes the
T82633 233-239 NN denotes fusion
T75213 240-247 NN denotes peptide
T29294 247-248 -COMMA- denotes ,
T28968 249-255 NN denotes heptad
T29760 256-262 NN denotes repeat
T53742 263-266 CD denotes one
T18725 266-267 -COMMA- denotes ,
T43420 268-271 CC denotes and
T34460 272-275 DT denotes the
T26621 276-283 JJ denotes central
T91466 284-289 NN denotes helix
T93319 290-297 NNS denotes domains
T88231 297-298 -COMMA- denotes ,
T49934 299-304 WDT denotes which
T23715 305-308 VBP denotes are
T33407 309-315 RB denotes likely
T88882 316-323 JJ denotes subject
T76117 324-326 TO denotes to
T4874 327-334 JJR denotes greater
T38302 335-345 JJ denotes functional
T99472 346-357 NNS denotes constraints
T34520 358-359 -LRB- denotes (
T48991 359-366 NN denotes Fig. 4a
T5319 366-367 -RRB- denotes )
R54626 T39186 T18701 arg1Of found,Firstly
R55552 T39186 T74266 arg1Of found,","
R48506 T36827 T39186 arg1Of we,found
R85227 T93591 T39186 arg2Of elevated,found
R94248 T93591 T6773 arg1Of elevated,that
R56819 T54008 T13224 arg1Of diversity,amino-acid
R12367 T54008 T35302 arg1Of diversity,was
R36961 T93591 T35302 arg2Of elevated,was
R67157 T54008 T93591 arg2Of diversity,elevated
R98710 T93591 T90961 arg1Of elevated,at
R55146 T86793 T90961 arg2Of epitopes,at
R5883 T86793 T69090 arg2Of epitopes,known
R17754 T32200 T61088 arg1Of antibodies,targeted
R9367 T86793 T61088 arg2Of epitopes,targeted
R83504 T32200 T53019 arg2Of antibodies,by
R74212 T32200 T30461 arg1Of antibodies,neutralizing
R10411 T32200 T83554 arg1Of antibodies,","
R98281 T51281 T32640 arg1Of as,such
R81049 T32200 T51281 arg1Of antibodies,as
R6966 T58919 T51281 arg2Of and,as
R21530 T49099 T69890 arg1Of domain,the
R64448 T49099 T83248 arg1Of domain,N-terminal
R49770 T49099 T58919 arg1Of domain,and
R65608 T60790 T58919 arg2Of domains,and
R95057 T60790 T18721 arg1Of domains,the
R69352 T60790 T18570 arg1Of domains,receptor-binding
R16170 T96660 T18812 arg1Of and,","
R74990 T61088 T96660 arg1Of targeted,and
R8726 T11216 T96660 arg2Of reduced,and
R71690 T86793 T11216 arg2Of epitopes,reduced
R89891 T11216 T27277 arg1Of reduced,in
R47563 T7777 T27277 arg2Of regions,in
R49965 T7777 T89562 arg1Of regions,the
R85283 T7777 T23472 arg1Of regions,in
R56401 T69246 T23472 arg2Of domain,in
R32729 T69246 T66095 arg1Of domain,the
R3287 T69246 T52990 arg1Of domain,S2
R10516 T86793 T76095 arg1Of epitopes,","
R16608 T94778 T33023 arg1Of as,such
R96223 T86793 T94778 arg1Of epitopes,as
R16738 T43420 T94778 arg2Of and,as
R3992 T75213 T12698 arg1Of peptide,the
R20067 T75213 T82633 arg1Of peptide,fusion
R62161 T75213 T29294 arg1Of peptide,","
R83184 T29760 T29294 arg2Of repeat,","
R27719 T29760 T28968 arg1Of repeat,heptad
R49150 T29760 T53742 arg1Of repeat,one
R38048 T43420 T18725 arg1Of and,","
R84039 T75213 T43420 arg1Of peptide,and
R65597 T93319 T43420 arg2Of domains,and
R93652 T93319 T34460 arg1Of domains,the
R84393 T93319 T26621 arg1Of domains,central
R23746 T93319 T91466 arg1Of domains,helix
R18674 T93319 T88231 arg1Of domains,","
R28527 T93319 T49934 arg1Of domains,which
R95251 T93319 T23715 arg1Of domains,are
R68137 T88882 T23715 arg2Of subject,are
R82494 T88882 T33407 arg1Of subject,likely
R84782 T93319 T88882 arg1Of domains,subject
R15085 T88882 T76117 arg1Of subject,to
R84300 T99472 T76117 arg2Of constraints,to
R3107 T99472 T4874 arg1Of constraints,greater
R96110 T99472 T38302 arg1Of constraints,functional
R31642 T99472 T34520 arg1Of constraints,(
R75726 T48991 T34520 arg2Of Fig. 4a,(
R85323 T5319 T34520 arg3Of ),(

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T90 23-33 Body_part denotes amino-acid http://purl.org/sig/ont/fma/fma82739
T91 284-289 Body_part denotes helix http://purl.org/sig/ont/fma/fma60992

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T126 23-28 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T127 240-247 Chemical denotes peptide http://purl.obolibrary.org/obo/CHEBI_16670

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T89 0-368 Sentence denotes Firstly, we found that amino-acid diversity was elevated at known epitopes targeted by neutralizing antibodies, such as the N-terminal domain and the receptor-binding domains, and reduced in the regions in the S2 domain, such as the fusion peptide, heptad repeat one, and the central helix domains, which are likely subject to greater functional constraints (Fig. 4a).

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T4 284-289 Body_part denotes helix http://purl.obolibrary.org/obo/UBERON_0002488

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T89 0-368 Sentence denotes Firstly, we found that amino-acid diversity was elevated at known epitopes targeted by neutralizing antibodies, such as the N-terminal domain and the receptor-binding domains, and reduced in the regions in the S2 domain, such as the fusion peptide, heptad repeat one, and the central helix domains, which are likely subject to greater functional constraints (Fig. 4a).